Characteristic	Details
Generic Name	Sildenafil Citrate
Dosage Forms	50 mg, 100 mg
Route of Administration	Oral
Therapeutic Category	Phosphodiesterase (PDE) Inhibitor
Visit Caverta Site

Pharmacokinetics of Caverta

The pharmacokinetics of Caverta play a crucial role in its efficacy. Administered orally, it is absorbed into the bloodstream within 30 to 120 minutes. Peak plasma concentrations are reached approximately one hour post-dose. The bioavailability of sildenafil is about 41% due to first-pass metabolism.

Caverta primarily metabolizes in the liver. It involves the CYP3A4 and CYP2C9 enzymes. Its metabolites exhibit comparable efficacy, although with reduced potency. The elimination half-life is approximately four hours. This duration supports its transient therapeutic effects.

Excretion is primarily via feces, with about 80% of the dose eliminated through this route. Renal excretion accounts for around 13%. These pharmacokinetic properties guide dosing and administration, ensuring optimal performance.

Areas of Use for Caverta

Caverta is indicated for treating erectile dysfunction (ED). It enhances erectile response during sexual stimulation. Its role in ED management is well-documented and globally recognized.

Beyond ED, sildenafil 100 mg shows promise in pulmonary arterial hypertension (PAH). By relaxing pulmonary blood vessels, it improves exercise capacity and symptoms. This dual utility emphasizes Caverta’s therapeutic versatility.

Additionally, investigational uses include managing Raynaud’s phenomenon and high-altitude pulmonary edema. These applications are under clinical scrutiny but reflect potential beyond conventional boundaries.

Precautions When Using Caverta

Caverta precautions center around contraindications and potential interactions. It is contraindicated in individuals with hypersensitivity to sildenafil. Patients using nitrates for cardiac conditions should avoid Caverta due to severe hypotension risk.

Precaution is advised for those with cardiovascular disease, renal impairment, or retinitis pigmentosa. Concomitant use with potent CYP3A4 inhibitors requires dosage adjustments. These precautions ensure safety and efficacy.

Pregnancy and Breastfeeding Considerations

Data on Caverta in pregnancy is limited. Its use in pregnant individuals is generally discouraged unless essential. Potential risks and benefits must be weighed carefully.

Breastfeeding while using Caverta lacks extensive research. It is prudent to err on the side of caution. Consulting healthcare professionals is imperative for personalized guidance.

Managing Caverta Side Effects

Caverta may induce side effects. Common ones include headache, flushing, and dyspepsia. These are usually transient and mild.

In cases of adverse reactions, dose adjustment or discontinuation may be necessary. Staying hydrated and monitoring symptoms can assist in alleviating discomfort.

Headache: Rest and hydration can help.
Flushing: A cool environment may ease symptoms.
Dyspepsia: Antacids may offer relief.

Caverta Over The Counter Availability

Over-the-counter availability of Caverta varies by region. In many jurisdictions, it requires a prescription. This ensures appropriate use and monitoring.

Online pharmacies offer access, yet caution is advised. Counterfeit products are a risk. Verification of sources is crucial for safety.

Regulatory frameworks dictate availability. It is advisable to consult healthcare professionals for guidance on procurement and use.

Potential Use	Status
Erectile Dysfunction	Approved
Pulmonary Arterial Hypertension	Approved
Raynaud’s Phenomenon	Investigational

Source:

Caverta: A Detailed Look